Faecal Microbiota Transplantation in Ulcerative Colitis (FOCUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01896635

Recruitment Status : Completed

First Posted : July 11, 2013

Last Update Posted : October 25, 2016

Sponsor:

Information provided by (Responsible Party):

Dr. Sudarshan Paramsothy, The University of New South Wales

Study Description

Brief Summary:

The purpose of this study is to determine whether fecal microbiota transplantation (FMT) is safe and efficacious in the treatment of chronic active ulcerative colitis (UC) by conducting a randomised controlled trial

Condition or disease	Intervention/treatment	Phase
Ulcerative Colitis Inflammatory Bowel Disease	Biological: FMT infusions Other: Placebo infusion	Phase 2

Detailed Description:

This study involves the assessment of the safety and efficacy of FMT in the treatment and induction of remission for patients with mild to moderate ulcerative colitis. It is a double blind study with patients randomised in a 1:1 manner to either active or placebo therapy

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	81 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	Faecal Microbiota Transplantation for Chronic Active Ulcerative Colitis - A Randomised Double Blind Controlled Study of Efficacy & Safety
Study Start Date :	November 2013
Actual Primary Completion Date :	November 2015
Actual Study Completion Date :	August 2016

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Ulcerative colitis

MedlinePlus related topics: Bowel Movement Ulcerative Colitis

Genetic and Rare Diseases Information Center resources: Chronic Graft Versus Host Disease

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: FMT infusions FMT infusions constituted from stool provided by healthy, screened donors	Biological: FMT infusions Active FMT derived from healthy anonymous pre-screened donors
Placebo Comparator: Placebo arm Placebo infusions	Other: Placebo infusion Placebo infusion not containing any donor microbial material

Outcome Measures

Primary Outcome Measures :

Composite Clinical remission & Endoscopic remission / response as measured by Mayo subscores [ Time Frame: 8 weeks ]

Secondary Outcome Measures :

Clinical remission as measured by Mayo subscores [ Time Frame: 8 weeks ]
Clinical response as measured by Mayo subscores [ Time Frame: 8 weeks ]
Endoscopic healing as measured by UCEIS [ Time Frame: 8 weeks ]
Treatment failure rate as defined by Mayo subscores [ Time Frame: 8 weeks ]
Quality of life as measured by IBDQ [ Time Frame: 8 weeks ]
Safety and tolerability as measured by adverse event data [ Time Frame: 8 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Ulcerative colitis >3 months duration
Active mild-moderate ulcerative colitis (Mayo 4-10)
Ulcerative colitis of any extent except isolated proctitis < 5cm
Live within driving distance of clinical site (to attend multiple study visits)

Exclusion Criteria:

Pregnancy
Active gastrointestinal infection
Other gastrointestinal disease / comorbidities
Prior colonic surgery
Recent antibiotic or probiotic use
Prednisone > 20mg
Monoclonal antibody immunosuppressive therapy

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01896635

Locations

Layout table for location information

Australia, New South Wales
St Vincent's Hospital
Sydney, New South Wales, Australia, 2010
Bankstown-Lidcombe Hospital
Sydney, New South Wales, Australia, 2200
Australia, Queensland
Nambour General Hospital
Nambour, Queensland, Australia, 4560

Sponsors and Collaborators

The University of New South Wales

Investigators

Layout table for investigator information

Principal Investigator:	Hazel Mitchell, BSc PhD	University of New South Wales
Principal Investigator:	Alissa Walsh, MBBS	St Vincent's Hospital, Sydney
Principal Investigator:	Johan van den Bogaerde, MBChB PhD	Nambour General Hospital, Queensland
Principal Investigator:	Douglas Samuel, MBBS MMed	Bankstown-Lidcombe Hospital, Sydney
Principal Investigator:	Nadeem O Kaakoush, BSc PhD	University of New South Wales
Principal Investigator:	Michael Kamm, MBBS MD	University of Melbourne

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Paramsothy S, Nielsen S, Kamm MA, Deshpande NP, Faith JJ, Clemente JC, Paramsothy R, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Lin E, Borody TJ, Wilkins MR, Colombel JF, Mitchell HM, Kaakoush NO. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. Gastroenterology. 2019 Apr;156(5):1440-1454.e2. doi: 10.1053/j.gastro.2018.12.001. Epub 2018 Dec 6.

Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017 Mar 25;389(10075):1218-1228. doi: 10.1016/S0140-6736(17)30182-4. Epub 2017 Feb 15.

Paramsothy S, Walsh AJ, Borody T, Samuel D, van den Bogaerde J, Leong RW, Connor S, Ng W, Mitchell HM, Kaakoush NO, Kamm MA. Gastroenterologist perceptions of faecal microbiota transplantation. World J Gastroenterol. 2015 Oct 14;21(38):10907-14. doi: 10.3748/wjg.v21.i38.10907.

Paramsothy S, Borody TJ, Lin E, Finlayson S, Walsh AJ, Samuel D, van den Bogaerde J, Leong RW, Connor S, Ng W, Mitchell HM, Kaakoush N, Kamm MA. Donor Recruitment for Fecal Microbiota Transplantation. Inflamm Bowel Dis. 2015 Jul;21(7):1600-6. doi: 10.1097/MIB.0000000000000405.

Layout table for additonal information

Responsible Party:	Dr. Sudarshan Paramsothy, Gastroenterologist / PhD candidate, The University of New South Wales
ClinicalTrials.gov Identifier:	NCT01896635
Other Study ID Numbers:	FOCUS
First Posted:	July 11, 2013 Key Record Dates
Last Update Posted:	October 25, 2016
Last Verified:	October 2016

Keywords provided by Dr. Sudarshan Paramsothy, The University of New South Wales:


Ulcerative Colitis Inflammatory Bowel Disease Fecal Transplantation Fecal Microbiota Transplantation

Additional relevant MeSH terms:

Layout table for MeSH terms

Colitis Colitis, Ulcerative Intestinal Diseases Inflammatory Bowel Diseases Ulcer	Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Colonic Diseases Pathologic Processes

To Top